Team Member (Name and Surname)	**Jérôme Parcq (PhD)**	
Position	CSO, Co-founder	
Skills & Accomplishments		
Jérôme's experience is complementary, with a 10-year focused background in stroke and neurovascular research. He also benefited from a training in entrepreneurship and has multidisciplinary skills highly compatible with innovative entrepreneurship, as required for Op2Lysis. Jérôme obtained 750 k€ public grants before the creation of Op2Lysis and is the author of 16 peer-reviewed publications and of the family of patents that protect O2L-001.		
Name	Description	
Project management	**>3.4M€ funds raised from fundamental research to IP protection and production of first Proofs of concept.**	
Communication skills	**16 peer-reviewed publications (IF>6) and 2 family of patent**	
Experience		
Function	**CSO**	
Company (Place)	**Op2Lysis (Paris, France)**	
Period: 2016 -		
Activities - Funding obtained: 3.4 M€, including dilutive and non-dilutive - Labels obtained: "young innovative company"; "CIFRE" convention - Analysis the competitive landscape to set up a value proposition - Business Plan redaction / IP rights management (2 families of patents and 2 negotiated licenses)		
Function	**Research project leader**	
Company (Place)	**Inserm (Caen, France)**	
Period: 2006-2016		
Activities - Project manager: action plan, budget, legal and workforce needed for success (i.e. production of radiolabeled recombinant protein (35S)), - >10 oral and written communication of ideas and results in major scientific congresses (Brain, US SfN), - Publications (16 peer-reviewed publications) / IP protection and valorization (1 patent family). - Production and & evaluation of an innovative technology for veterinary application		
Education		
Place	year	Title
HEC Challenge+	**2012**	
University of Caen	**2010 – Ph.D. In Neurosciences**	
Agrocampus Ouest	**2006 – Master grade/ engineer in Agronomy**	

Team Member (Name and Surname)	**Christophe Gaudin (M.D.)**
Position	CEO, co-funder
Skills & Accomplishments	
Christophe's track record with a successful 20-year drug development experience in pharma industry at Sanofi - including international registration (US, EU and Japan) of anti-thrombotic blockbusters (Plavix®, Lovenox®) for ischemic diseases such as heart attack and of a new chemical entity (Multaq®) for the treatment of patients with atrial fibrillation - is a perfect fit to the purpose of the proposed development structure dedicated to O2L-001. Christophe is the author of 60 peer-reviewed publications and 13 use patents.	
Name	Description
Business Growth	**Contribution to the successful growth of a leading pharmaceutical Company in the cardiovascular and thrombosis (CV&T) field – a portfolio of more than 7 Billion € in yearly sales.**
Clinical development	**Successful worldwide registration of new chemical entities (NDA) and Life Cycle Management (LCM) indications of blockbusters, including Plavix, Lovenox, Multaq**
Discussions with Health Authorities	**Broad experience in interactions with Health Authorities, mainly in US, Europe and Japan (pre-IND and end of phase I or II meetings at FDA, review of CTD/NDA and questions and answers, FDA Advisory Committees, CHMP scientific advices and hearings, PMDA official meetings, and other local agencies)**
Experience	
Function	**CEO**
Company (Place)	**Op2Lysis (Boulogne-Billancourt, France)**
Period 2016-ongoing	
Activities Company creation and fundraising up to 3.4 M€, including dilutive and non-dilutive Chair of Strategic Committee and communication with shareholders Hired a team of 2+ employees and co-managed the advancement of the project to ensure delivery on time with the resources raised	
Function	**Increasing responsibilities from Clinical research Director to Vice-President, Head of cardiovascular and thrombosis clinical investigations, Global Project Head, and Head of Early Development, Cardiovascular and Fibrosis Research Unit**
Company (Place)	**Sanofi (Chilly Mazarin, France)**
Period: 1997-2017	
Activities Increasing drug development responsibilities to allow worldwide access of patients to life-saving drugs in then cardiovascular and thrombosis therapeutic area. Matrix and direct management of international multi-site teams, including partner companies. Successful lead of R&D development projects, broad experience in interactions with Health Authorities in US, EU and Japan	

Function	**Project Manager/Associate Director of Clinical Pharmacology**	
Company (Place)	**Institut de Recherche Jouveinal-Parke-Davis, (Fresnes, France)**	
Period: 1994-1997		
Activities Clinical lead of early phase programs in immune-inflammation and digestive diseases		
Function	**Research Fellow, Molecular Cardiology**	
Company (Place)	**Lederle-American Cyanamid, Pearl River, NY, USA**	
Period: 1990-1993		
Activities Post-Doctoral fellowship, Harvard Medical School, then Columbia University Conduct of a research project on cardiac beta-adrenergic signal transduction, including the development of a mouse transgenic line overexpressing cardiac Gs(-alpha protein.		
Education		
Place	year	Title
University of Paris	**1984 – Medical Degree** **1986 – Board Certified specialist, Master's in Physics and Certified in Statistics**	